Discovery of new non-macrocyclic TRK inhibitors based on conformational flexibility and scaffold hopping to overcome clinical acquired resistance

Key Points

• New TRK inhibitors show effectiveness against cancer and target acquired resistance mechanisms.
• Key evidence indicates a successful scaffold hopping approach, enhancing drug flexibility and efficacy.
• The methods involve innovative screening of conformationally flexible compounds to identify non-macrocyclic TRK inhibitors.
• This work highlights the potential for better cancer treatment options, but clinical studies are needed to confirm effectiveness.